GBP9.80
0.12% day before yesterday
London, Dec 06, 05:37 pm CET
ISIN
GB0009223206
Symbol
SN
Sector

Smith & Nephew Stock price

GBP9.80
+0.52 5.63% 1M
-0.42 4.07% 6M
-0.61 5.90% YTD
-0.13 1.32% 1Y
-1.59 13.93% 3Y
-4.52 31.55% 5Y
+1.35 15.92% 10Y
London, Closing price Fri, Dec 06 2024
+0.01 0.12%
ISIN
GB0009223206
Symbol
SN
Sector

Key metrics

Market capitalization GBP8.55b
Enterprise Value GBP10.99b
P/E (TTM) P/E ratio 35.33
EV/FCF (TTM) EV/FCF 45.70
EV/Sales (TTM) EV/Sales 2.45
P/S ratio (TTM) P/S ratio 1.91
P/B ratio (TTM) P/B ratio 2.08
Dividend yield 3.83%
Last dividend (FY23) GBP0.38
Revenue growth (TTM) Revenue growth 0.85%
Revenue (TTM) Revenue GBP4.48b
EBIT (operating result TTM) EBIT GBP661.15m
Free Cash Flow (TTM) Free Cash Flow GBP240.42m
EPS (TTM) EPS GBP0.28
P/E forward 26.52
P/S forward 1.88
EV/Sales forward 2.41
Short interest 203.00%
Show more

Is Smith & Nephew a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.

Smith & Nephew Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Smith & Nephew forecast:

11x Buy
55%
9x Hold
45%

Analyst Opinions

20 Analysts have issued a Smith & Nephew forecast:

Buy
55%
Hold
45%

Financial data from Smith & Nephew

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
4,482 4,482
1% 1%
100%
- Direct Costs 1,388 1,388
4% 4%
31%
3,094 3,094
1% 1%
69%
- Selling and Administrative Expenses 1,662 1,662
6% 6%
37%
- Research and Development Expense 246 246
12% 12%
5%
1,185 1,185
11% 11%
26%
- Depreciation and Amortization 524 524
4% 4%
12%
EBIT (Operating Income) EBIT 661 661
17% 17%
15%
Net Profit 242 242
35% 35%
5%

In millions GBP.

Don't miss a Thing! We will send you all news about Smith & Nephew directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Deepak Nath
Employees 19,551
Founded 1856
Website www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today